A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Demcizumab (Primary) ; Paclitaxel (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms Yosemite
- Sponsors OncoMed Pharmaceuticals
- 13 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Jan 2018.
- 13 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017.
- 10 Apr 2017 According to an OncoMed Pharmaceuticals media release, the company will be discontinuing this trial due to lack of benefit over standard-of-care.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History